• 靶点：
• IL-4R/CD124

• 简介：
• >>Cytokine-cytokine receptor interaction;>>PI3K-Akt signaling pathway;>>JAK-STAT signaling pathway;>>Hematopoietic cell lineage;>>Th1 and Th2 cell differentiation;>>Th17 cell differentiation;>>Pathways in cancer;>>Inflammatory bowel disease

• 基因名称：
• IL4R

• 蛋白名称：
• Interleukin-4 receptor subunit alpha

• Human Gene Id：
• 3566

• Human Swiss Prot No：
• P24394

• Mouse Gene Id：
• 16190

• Mouse Swiss Prot No：
• P16382

• 免疫原：
• The antiserum was produced against synthesized peptide derived from human IL-4R/CD124. AA range:463-512

• 特异性：
• IL-4Rα Polyclonal Antibody detects endogenous levels of IL-4Rα protein.

• 组成：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• 来源：
• Polyclonal, Rabbit,IgG

• 稀释：
• WB 1:500 - 1:2000. IF 1:200 - 1:1000. ELISA: 1:20000. Not yet tested in other applications.

• 纯化工艺：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• 浓度：
• 1 mg/ml

• 储存：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• 其他名称：
• IL4R;IL4RA;582J2.1;Interleukin-4 receptor subunit alpha;IL-4 receptor subunit alpha;IL-4R subunit alpha;IL-4R-alpha;IL-4RA;CD antigen CD124

• 实测条带：
• 90kD

• 背景：
• This gene encodes the alpha chain of the interleukin-4 receptor, a type I transmembrane protein that can bind interleukin 4 and interleukin 13 to regulate IgE production. The encoded protein also can bind interleukin 4 to promote differentiation of Th2 cells. A soluble form of the encoded protein can be produced by proteolysis of the membrane-bound protein, and this soluble form can inhibit IL4-mediated cell proliferation and IL5 upregulation by T-cells. Allelic variations in this gene have been associated with atopy, a condition that can manifest itself as allergic rhinitis, sinusitus, asthma, or eczema. Polymorphisms in this gene are also associated with resistance to human immunodeficiency virus type-1 infection. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Apr 2012],

• 功能：
• domain:Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.,domain:The box 1 motif is required for JAK interaction and/or activation.,domain:The extracellular domain represents the IL4 binding protein (IL4BP).,domain:The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.,function:Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammmation. In certain cel

• 细胞定位：
• Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.

• 组织表达：
• Isoform 1 and isoform 2 are highly expressed in activated T-cells.

M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death & Disease Cell Death Dis. 2018 Jul;9(7):1-13 IF Human 1:400 prostate tissue prostate fibroblasts
货号：YT2337

M2 macrophage-mediated interleukin-4 signalling induces myofibroblast phenotype during the progression of benign prostatic hyperplasia. Cell Death & Disease Cell Death Dis. 2018 Jul;9(7):1-13 WB Human 1:1000 prostate tissue prostate fibroblasts
货号：YT2337

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs